Artiva Biotherapeutics (ARTV) Cash from Financing Activities (2023 - 2026)
Artiva Biotherapeutics (ARTV) reported Cash from Financing Activities of -$112000.0 for Q1 2026, down 146.86% year-over-year from $239000.0 in Q1 2025, and up 7.44% quarter-over-quarter from -$121000.0 in Q4 2025.
Artiva Biotherapeutics (ARTV) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has 4 years of Cash from Financing Activities data on file, last reported at -$112000.0 in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$112000.0, down 146.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$342000.0 (down 100.21% YoY), and the FY2025 annual result was $9000.0, down 99.99% from the prior year.
- Cash from Financing Activities climbed to -$112000.0 in Q1 2026 per ARTV's latest filing, from -$121000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $163.9 million in Q3 2024 and troughed at -$121000.0 in Q4 2025.
- A 4-year average of $20.9 million and a median of -$30000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities jumped 599.38% in 2024, then plunged 303.33% in 2025.
- A 4-year view of Cash from Financing Activities shows it stood at $962000.0 in 2023, then plunged by 103.12% to -$30000.0 in 2024, then sank by 303.33% to -$121000.0 in 2025, then increased by 7.44% to -$112000.0 in 2026.
- Business Quant data shows ARTV's Cash from Financing Activities at -$112000.0 in Q1 2026, -$121000.0 in Q4 2025, and -$37000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Artiva Biotherapeutics | 241.85 Mn | 241.85 Mn | - | -112,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -112,000.00 |
| Mar 31, 2026 | -112,000.00 |
| Dec 31, 2025 | -121,000.00 |
| Dec 31, 2025 | -121,000.00 |
| Sep 30, 2025 | -37,000.00 |
| Sep 30, 2025 | -37,000.00 |
| Jun 30, 2025 | -72,000.00 |
| Jun 30, 2025 | -72,000.00 |
| Mar 31, 2025 | 239,000.00 |
| Mar 31, 2025 | 239,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Sep 30, 2024 | 163.87 Mn |
| Sep 30, 2024 | 163.87 Mn |
| Dec 31, 2023 | 962,000.00 |
| Dec 31, 2023 | 962,000.00 |
| Sep 30, 2023 | 23.43 Mn |
| Sep 30, 2023 | 23.43 Mn |